Immune response of fractional doses of Inactivated Poliovirus Vaccine (IPV) administered intradermally in Cuba

Submission date Recruitment status Prospectively registered 14/08/2007 No longer recruiting [] Protocol Statistical analysis plan Registration date Overall study status 15/08/2007 Completed [X] Results Individual participant data Last Edited Condition category 30/09/2021 Infections and Infestations

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Anna-Lea Kahn

Contact details

Technical Officer
World Health Organization
20 Avenue Appia
Geneva-27
Switzerland
CH-1211
+41 (0)22 791 3135
kahna@who.int

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Immune response of fractional doses of Inactivated Poliovirus Vaccine (IPV) administered intradermally in Cuba

Study objectives

- 1. Does a schedule of three fractional 0.1 ml IPV doses administered intradermally (intervention) provide comparable seroconversion and titre with a three-dose schedule of full 0.5 ml IPV doses (control) administered intramuscularly at 6, 10, and 14 weeks?
- 2. What is the contribution to seroconversion and titre in each group after the first, second and third dose of study vaccines?
- 3. What is the influence of maternally-derived antibodies on seroconversion and titre?
- 4. Does each study arm have comparable adverse events systemic and local (the intervention group receives fractional doses by needle-free device, while the control group receives full doses by intramuscular injection by needle and syringe)?
- 5. Do mothers whose study infants were vaccinated by needle-free device (study) and needle and syringe (routine program) express a preference for route for administration after the third vaccination?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval from:

- 1. World Health Organization (WHO) Research Ethics Review Committee on the 11th September 2006 (ref: RPC171)
- 2. Medical ethics committee of the Tropical Medicine Institute (Instituto de Medicina Tropical Pedro Kouri [IPK]) on the 17th August 2006

Study design

Randomised controlled clinical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Poliomyelitis vaccination

Interventions

Patients will be randomised between:

- 1. A fractional dose of IPV (0.1 ml or 1/5 of a dose) administered intradermally by needle-free device potency of IPV is 40-8-32-D antigen units
- 2. A full dose of IPV (0.5 ml) administered intramuscularly by needle and syringe potency of IPV is 40-8-32-D antigen units

Principal Investigator:

Dr Pedro Mas Lago

c/o Instituto de Medicina Tropical Pedro Kouri (IPK)

Ministerio de Salud Publica

P.O. Box 601

Havana, Mariana 13

Cuba

Tel: +53 (0)7 202 0430 Fax: +53 (0)7 204 6051 Email: pmasl@ipk.sld.cu

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Inactivated Poliovirus Vaccine (IPV)

Primary outcome measure

Seroconversion by neutralisation assay between birth and 18 weeks.

Secondary outcome measures

Seroconversion by neutralisation assay after each dose of study vaccines.

Overall study start date

15/09/2006

Completion date

30/04/2007

Eligibility

Key inclusion criteria

- 1. Healthy newborns (greater than 2.5 kg, apgar score greater than 9 at five minutes)
- 2. Living within the catchment area of the participating polyclinics
- 3. Newborns delivered by caesarian section

Participant type(s)

Patient

Age group

Neonate

Sex

Both

Target number of participants

400

Total final enrolment

320

Key exclusion criteria

- 1. Newborns requiring hospitalisation (except if in hospital because of maternal admission)
- 2. Birth weight below 2.5 kg
- 3. Apgar score less than 9
- 4. Residence outside the catchment area, or families expecting to move away during the study period
- 5. A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family) will also render the newborn ineligible for the study

Date of first enrolment

15/09/2006

Date of final enrolment

30/04/2007

Locations

Countries of recruitment

Cuba

Switzerland

Study participating centre Technical Officer

Geneva-27 Switzerland CH-1211

Sponsor information

Organisation

World Health Organization (WHO) (Switzerland)

Sponsor details

20 Avenue Appia Geneva-27 Switzerland CH-1211

Sponsor type

Research organisation

Website

http://www.polioeradication.org/content/fixed/opvcessation/opvcessation.asp

ROR

https://ror.org/01f80g185

Funder(s)

Funder type

Research organisation

Funder Name

World Health Organization (WHO)/Polio Eradication Initiative (POL) (Switzerland)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	31/01/2013	30/09/2021	Yes	No